
## Tarek Magdy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4689078/publications.pdf Version: 2024-02-01



TADEK MACDY

#	Article	IF	CITATIONS
1	PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Research, 2011, 39, 5284-5298.	14.5	199
2	Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cells to Assess Drug Cardiotoxicity: Opportunities and Problems. Annual Review of Pharmacology and Toxicology, 2018, 58, 83-103.	9.4	89
3	Negligible-Cost and Weekend-Free Chemically Defined Human iPSC Culture. Stem Cell Reports, 2020, 14, 256-270.	4.8	80
4	Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?. , 2016, 168, 113-125.		61
5	Solid formulation of cell-penetrating peptide nanocomplexes with siRNA and their stability in simulated gastric conditions. Journal of Controlled Release, 2012, 162, 1-8.	9.9	51
6	Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity. Circulation, 2022, 145, 279-294.	1.6	46
7	Role of ABC Transporters in Fluoropyrimidine-Based Chemotherapy Response. Advances in Cancer Research, 2015, 125, 217-243.	5.0	43
8	RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy. Cell Stem Cell, 2021, 28, 2076-2089.e7.	11.1	36
9	Targeting OCT3 attenuates doxorubicin-induced cardiac injury. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	33
10	Association of <i>GSTM1</i> null variant with anthracyclineâ€related cardiomyopathy after childhood cancer—A Children's Oncology Group ALTE03N1 report. Cancer, 2020, 126, 4051-4058.	4.1	23
11	<i>ABCC11</i> /MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression. Pharmacogenomics, 2013, 14, 1433-1448.	1.3	21
12	Human In Vitro Models for Assessing the Genomic Basis of Chemotherapy-Induced Cardiovascular Toxicity. Journal of Cardiovascular Translational Research, 2020, 13, 377-389.	2.4	11
13	The future role of pharmacogenomics in anticancer agent-induced cardiovascular toxicity. Pharmacogenomics, 2018, 19, 79-82.	1.3	10
14	Precise and Cost-Effective Nanopore Sequencing for Post-GWAS Fine-Mapping and Causal Variant Identification. IScience, 2020, 23, 100971.	4.1	7
15	Unraveling Difficult Answers: From Genotype to Phenotype in Coronary Artery Disease. Cell Stem Cell, 2019, 24, 203-205.	11.1	5
16	Use of hiPSC to explicate genomic predisposition to anthracycline-induced cardiotoxicity. Pharmacogenomics, 2021, 22, 41-54.	1.3	4
17	A novel association between GSTM1 null variant and anthracycline-induced cardiac dysfunction (ACD) in childhood cancer survivors (CCS): A COG ALTE03N1 report Journal of Clinical Oncology, 2019, 37, 10030-10030.	1.6	0
18	Prime time for doxorubicin-induced cardiotoxicity genetic testing. Pharmacogenomics, 2022, 23, 335-338.	1.3	0